Three Days of Deflazacort in Early Pregnancy: Safety Assessment
A three-day course of deflazacort in early pregnancy carries a small but measurable risk of orofacial clefts (increasing baseline risk from 1/1,000 to 3-5/1,000 infants), but this short exposure is unlikely to cause major harm and does not warrant pregnancy termination.
Risk Profile Based on FDA Labeling
The FDA label for deflazacort clearly states that corticosteroids, including deflazacort, readily cross the placenta 1. The primary concerns with first-trimester exposure are:
- Orofacial clefts: Risk increases from approximately 1 per 1,000 to 3-5 per 1,000 infants with maternal corticosteroid use during the first trimester 1
- Intrauterine growth restriction and decreased birth weight: These appear dose-related and are more concerning with prolonged exposure 1
- Neonatal hypoadrenalism: Infants born to mothers receiving substantial doses should be observed for signs of adrenal suppression 1
Clinical Context: Short Duration Matters
Your patient's three-day exposure is critical context. The FDA labeling emphasizes that intrauterine growth restriction and decreased birth weight are dose-related, and the underlying maternal condition also contributes to these risks 1. The most recent EULAR guidelines (2025) recommend restrictive use of oral glucocorticoids in pregnancy, noting that adverse effects occur with "prolonged period at higher doses" and that daily doses ≤5 mg are associated with low risk 2.
Key distinction: The teratogenic risk for orofacial clefts is primarily associated with first-trimester exposure, but three days represents minimal exposure compared to the chronic use patterns that drive most adverse outcomes.
Practical Management Approach
Immediate actions:
- Discontinue deflazacort immediately now that pregnancy is confirmed
- Counsel the patient about the small absolute increase in cleft risk (2-4 additional cases per 1,000 pregnancies)
- Document the exposure timing and duration precisely
Monitoring plan:
- Standard prenatal care with detailed fetal anatomic ultrasound at 18-22 weeks, with particular attention to facial structures
- No additional interventions are required beyond routine prenatal screening
- Observe the neonate for signs of hypoadrenalism if delivery occurs (though unlikely with such brief exposure)
Evidence Synthesis
The 2020 ACR guidelines emphasize switching to pregnancy-compatible medications before conception when possible 3, but this patient's situation involves inadvertent exposure. Research specifically on deflazacort in pregnancy is limited—one study in kidney transplant patients suggested deflazacort may decrease clinical pregnancy rates when used during conception attempts 4, but this addresses fertility rather than teratogenicity after conception has occurred.
Critical caveat: The FDA states there are "no adequate and well-controlled studies with deflazacort in pregnant women" 1, so risk estimates are extrapolated from other corticosteroids. However, the class effect of corticosteroids on cleft palate is well-established across multiple agents.
Bottom Line
Do not terminate this pregnancy based on three days of deflazacort exposure. The absolute risk increase is small, the exposure was brief and early, and the dose-dependent adverse effects (growth restriction, decreased birth weight) are primarily associated with prolonged use. Provide reassurance while acknowledging the small increased cleft risk, ensure appropriate prenatal screening, and avoid further corticosteroid exposure unless medically essential for maternal health.